Cabozantinib 60 mg Tablets UK

is a once-daily oral targeted therapy for advanced kidney, liver, and medullary thyroid cancers. It works by blocking cancer cell growth and angiogenesis via inhibition of multiple tyrosine kinase receptors. This 60 mg strength is the standard starting dose for most adult patients. Must be taken under the supervision of a healthcare provider.

Cabozantinib Tablets 60 mg is an oral targeted therapy used in the treatment of advanced kidney cancer (renal cell carcinoma – RCC), liver cancer (hepatocellular carcinoma – HCC), and medullary thyroid cancer (MTC). It belongs to a class of medications called tyrosine kinase inhibitors (TKIs) and works by blocking multiple cancer-driving proteins involved in tumor growth, metastasis, and angiogenesis (formation of new blood vessels).

This 60 mg strength is the standard recommended daily dose for adult patients with advanced-stage cancers, administered once daily on an empty stomach.

What Is Cabozantinib Used For?

Cabozantinib 60 mg is indicated for the treatment of:

• Advanced Renal Cell Carcinoma (RCC) in adults

• Hepatocellular Carcinoma (HCC) in patients previously treated with sorafenib

• Progressive or Metastatic Medullary Thyroid Cancer (MTC)

It may be used as a monotherapy or in combination with immune checkpoint inhibitors under specialized clinical protocols.

How Cabozantinib Works

Cabozantinib blocks multiple tyrosine kinases including:

• VEGFR-1, VEGFR-2, VEGFR-3

• MET

• AXL and RET

These receptors are involved in critical pathways that control:

• Tumor cell growth and survival

• Angiogenesis (blood vessel growth)

• Cell migration and metastasis

By inhibiting these pathways, Cabozantinib slows or halts disease progression, starves tumors of nutrients, and may shrink tumor size.

Dosage and Administration

• Usual Adult Dose: 60 mg once daily

• Form: Oral tablet, film-coated

• Administration Guidelines:

  • Take once daily on an empty stomach

  • No food for at least 2 hours before and 1 hour after taking the tablet

  • Swallow whole. Do not cut or crush.

Dosage may be reduced based on tolerance or side effects. Other strengths (20 and 40 mg) may be used for dose adjustment.

Composition

• Active Ingredient: Cabozantinib (as Cabozantinib S-malate) 60 mg

• Dosage Form: Oral film-coated tablet

• Packaging: Available in strips or bottles, typically 28 or 30 tablets per pack

Side Effects

Common Side Effects

• Fatigue

• Diarrhea

• Decreased appetite

• Nausea

• Weight loss

• Mouth sores

• High blood pressure

• Hand-foot syndrome

Serious Side Effects

• Gastrointestinal perforation

• Hemorrhage

• Liver toxicity

• Blood clots

• QT interval prolongation

• Wound healing complications

Patients will need regular blood tests and monitoring during treatment.

Warnings and Precautions

• Pregnancy: May harm an unborn baby. Contraception is required during and after therapy.

• Breastfeeding: Not recommended during treatment and for at least 4 months afterward.

• Hepatic or Renal Impairment: Use with caution; dose adjustment may be necessary.

• Drug Interactions: Avoid with strong CYP3A4 inducers/inhibitors unless medically necessary.

• Surgery: Discontinue Cabozantinib 2 weeks before major surgery.

Storage

• Store below 30°C (86°F)

• Keep the container tightly closed to protect from moisture

• Do not use beyond the expiry date

• Keep out of reach of children